Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-237 drug-drug interaction study with clarithromycin and rifampicin in healthy adult male volunteers
jRCT2051210203Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ursodeoxycholic acid, clarithromycin and rifampicin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Kowa Company, Ltd. Primary endpoints: Plasma pharmacokinetic parameters, Cmax of K-237 and 1 more. Started May 2022; status: completed.
02
Drugs
ursodeoxycholic acidclarithromycinrifampicin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2051210203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210203.